Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Gynaecology
  4. Back
  5. Gynaecology guidelines
  6. Women Who Refuse Blood Products, Gynaecology (319)
Announcements and latest updates

Right Decision Service newsletter: April 2024

Welcome to the Right Decision Service (RDS) newsletter for April 2024. 

Issues with RDS and Umbraco access

Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May.  If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.

Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.

Thank you for your patience and understanding while we achieve a full resolution.

Promotion and communication resources

A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.

Redesign and improvements to RDS

The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.

The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.

Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.

Figure 1: Impact of RDS on direct delivery of care

Key figures

  • 93% say that RDS has improved evidence-informed practice (high impact 62%; some impact 31%)
  • 91% report that RDS has improved consistency in practice (high impact 65%, some impact 26%)
  • 85% say that RDS has improved patient safety (high impact 59%, some impact 26%)
  • Although shared decision-making tools are only a recent addition to RDS, and only represent a small proportion of the current toolset, 85% of respondents still said that RDS had delivered impact in this area (53% high impact, 32% some impact.) 92% anticipate that RDS will deliver impact on shared decision-making in future and 85% believe it will improve delivery of personalised care in future.

Figure 2 shows RDS impact to date on delivery of health and care services

 

Key figures

These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.

Saving time and money

  • RDS clearly has a strong impact on saving practitioner time, with 90% of respondents reporting that this is the case. 65% say it has a high impact; 25% say it has some impact on time-saving.
  • It supports devolved decision-making across the multi-professional team (85% of respondents)
  • 76% of respondents confirm that it saves money compared, for example, to investing in commercial apps (54% high impact; 22% some impact.)
  • 72% believe it has impacted already on saving money and reducing waste in the way services are delivered – e.g. reducing costs of referral management, prescribing, admissions.

Quality assurance and governance

  • RDS leads are clear that RDS has improved local governance of guidelines, with 87% confirming that this is the case. (62% high impact; 25% some impact.)

Service innovation and workforce development

  • RDS is a major driver for service innovation and improvement (83% of respondents) and has impacted significantly on workforce knowledge and skills (92% of respondents – 66% high impact; 26% some impact).

New toolkits

A few examples of toolkits published to live in the last month:

Toolkits in development

Some of the toolkits the RDS team is currently working on:

  • SARCS (Sexual Assault Response Coordination Service)
  • Staffing method framework – Care Inspectorate.
  • SIGN 171 - Diabetes in pregnancy
  • SIGN 158 – British Guideline on Management of Asthma. Selected sections will be incorporated into the RDS, and complemented by a new chronic asthma pathway being developed by SIGN, British Thoracic Society and NICE.
  • Clinical pathways from NHS Fife and NHS Lanarkshire

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Quality audit of RDS toolkits

Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions.  We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.

Implementation projects

Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine.  The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Women Who Refuse Blood Products, Gynaecology (319)

Warning

Please report any inaccuracies or issues with this guideline using our online form

Background and Beliefs

Most women will accept a blood transfusion if there is a clinical need and they are fully informed. Some patients may refuse transfusion due to specific personal or religious beliefs. The main group of patients who refuse transfusion of allogenic blood or primary blood components (red cells, white cells, plasma and platelets) are practicing Jehovah’s Witnesses.

The Jehovah’s Witness movement is a Christian organisation in which members believe they should not receive allogenic blood due to their interpretation of a passage in the Bible; this is a deeply held core value. It is generally assumed that followers of the Jehovah’s Witness discipline have religious convictions that urge them to decline a blood transfusion, even when conditions are dire. There are also people who may decline a blood transfusion for other personal reasons.

Pre-donation and storage of autologous blood may also not be acceptable to these individuals. Additionally, procedures involving the use of autologous blood such as cell salvage are a matter of personal choice and may depend on whether the equipment is constantly linked to the patient’s circulation and there is no storage of the patient’s blood. However, Jehovah’s Witnesses’ religious understanding does not absolutely prohibit the use of fractions such as albumin, coagulation factors, immunoglobulins and haemophiliac preparations; each Jehovah’s Witness must decide individually if she can accept them (Watchtower 2007).

Unconscious Patients

In the management of an unconscious adult (e.g. ruptured ectopic pregnancy) the status may be unknown. Most practicing Jehovah’s Witnesses will carry a clear Advance Directive/Release card with them at all times. This is a legal document and, if in clear and unambiguous terms, should be respected. Contact could also be made with the patient’s GP who may hold a copy of such an Advance Directive.

Every effort should be made to avoid the use of blood and blood products in the perioperative period under these circumstances, however if a patient is unable to give an opinion, and no applicable advance directive exists, then the clinical judgement of the doctor should take precedence over the opinion of relatives or associates and this may include the administration of blood products. GMC guidance on patients who refuse treatment affirms this stating that: ‘In an emergency, you can provide treatment that is immediately necessary to save life or prevent deterioration in health without consent’ (Personal Beliefs and Medical Practice, paragraph 27 [GMC, 2013]). 

Any blood or blood products administered without prior patient consent should be clearly documented in the casenotes and it is the clinician’s duty to inform the patient about its use and the reasoning for this as soon as possible.

Clinical Management of Adults

Pre-Operative Management:

  • Consideration should be given to non-surgical management of condition where possible e.g. Uterine Artery Embolisation versus Myomectomy; medical management of menorrhagia etc.
  • It is acceptable for a surgeon to refuse to perform an elective procedure on the basis that they feel the risk to the patient from refusal of blood products outweighs the benefits of the procedure provided they refer the patient to another doctor if she wishes, and clearly document the reasoning to avoid accusations of religious discrimination (Personal Beliefs and Medical Practice, GMC 2013).
  • Establish with each Jehovah’s Witness patient which derivatives of the primary blood components are acceptable if any, and also whether procedures involving the patient’s own blood such as cell salvage or haemodialysis are acceptable. Patients should be asked explicitly about situations in which loss of life or limb are likely to confirm that their refusal extends to include these circumstances.
  • Document a clear record in the medical records and care plan regarding what the woman will accept.
  • Complete the Refusal of Blood Transfusion Form and file in the casenotes (to be scanned onto Clinical Portal). Complete the Advanced Directive if this is available.
  • Arrange pre-operative Anaesthetic review.
  • Assess the patient for personal or family history of unexpected bleeding or clotting issues following medical or dental procedures.
  • Avoid any medication that can increase blood loss, including NSAIDs, aspirin and vitamin K antagonists.
  • Establish a plan for emergency management of haemorrhage and damage control strategies for reducing risk to life and limb of the patient. Inform all relevant team members and any external departments that may be required if emergency occurs.
  • Baseline haemoglobin and serum ferritin should be checked well in advance of theatre date to allow early consideration to giving haematinics or parenteral iron if indicated.
  • Early discussion of an individual case with a Haematologist may be beneficial. Consider use of recombinant erythropoietin (EPO) several weeks pre-op.
  • Liaise regarding the availability of cell salvage for the procedure.

Intra-Operative Management

  • Inform Consultant Gynaecologist and Anaesthetist if a patient declining blood transfusion is admitted as an emergency.
  • Each surgical procedure should be managed routinely, by the most senior medical staff available. Junior medical staff should not conduct these procedures unless in an emergency situation where waiting on the arrival of more senior staff would be detrimental.
  • A Consultant Gynaecologist should be present at any surgical intervention if possible.
  • Consider operative approaches or techniques that can minimise the loss of blood and/or interventional radiology.
  • Where appropriate and acceptable to the patient consider the use of intraoperative autologous procedures such as cell salvage (which should be available for all elective procedures if required) and acute normovolaemic haemodilution. Consider early use of coagulation stimulants such as tranexamic acid, recombinant clotting factors (e.g. VIIa, VIII, IX) and desmopressin where appropriate.
  • Meticulous attention to haemostasis throughout the procedure and topical absorbable haemostatic agents may be appropriate.

Post-Operative Care:

  • A post-operative NEWS chart should be commenced and prompt review by medical staff for any score above 3.
  • After discharge, women should be advised to promptly report any increased bleeding.
  • Haematinics should be continued unless blood loss deemed to be minimal. Iron supplementation should be augmented with Folic Acid and Ascorbic Acid supplementation.
  • Thromboprophylaxis risk assessment and therapy should follow standard process.

Management of Haemorrhage:

This should be as for all patients with haemorrhage but with early consideration to the additional aspects below: 

  • Involvement of senior medical staff including the Haematologist
  • Use of IV Tranexamic Acid.
  • If available and acceptable to the patient, cell salvage may be life-saving if there is substantial blood loss.
  • If standard treatment is not controlling the bleeding, she should be advised (if not under general anaesthetic) that blood transfusion is strongly recommended.
  • If the woman dies, debriefing and support should be provided to family and staff involved.

Legal and Ethical Aspects

A competent adult is legally and ethically entitled to accept or refuse any specific treatment or procedure even though this decision may endanger her life. To administer blood in the face of refusal by a competent adult is unlawful, ethically unacceptable and may lead to criminal +/- civil proceedings.

For patients under the age of 16, blood products can be administered in a lifethreatening haemorrhage to prevent lasting disability without patient or parental consent. Two consultants should agree and document the clinical urgency for blood administration. Legal permission for treatment in the face of parental refusal should be sought at the earliest available opportunity.

Any patient is entitled to change her mind about a previously agreed treatment plan.

The doctor must be satisfied that the woman is not being subjected to pressure from others. It is reasonable to ask any accompanying persons to leave the room so that the doctor (with a witness) can ask her if she is making her decision of her own free will. If she maintains her refusal to accept blood or blood products, her wishes must be respected. No other person is legally able to consent to treatment for that adult or refuse treatment on that person’s behalf.

Help and Advice

The Hospital Liaison Committee can be contacted as a resource for more information 24/7 regarding the non-blood management of Jehovah’s Witnesses.

Harry Crawford    
Tel 01355 220674
Mob 07711 367409
harry@harry-crawford.com
John Allum   
Tel 0141 641 6206
Mob 07836 704774
johnallum@hlcglasgow.co.uk
John Flack
Tel 01360 621865
Mob 07775 837513
johnflack0802@aol.com

Editorial Information

Last reviewed: 01/02/2019

Next review date: 28/02/2024

Author(s): Ruth Jewell.

Approved By: Gynaecology Clinical Governance Group

Document Id: 319

References

Protocol For Patients Who Refuse Blood, NHS GG&C 2016 [Staffnet link]

Women Who Refuse Blood Products, Guideline for Management (Obstetrics). NHS GGC Obstetric Guidelines, 2018

Consent Form For the Refusal of Blood Transfusion [Staffnet link]

Jehovah’s Witness Management, Paediatric Patients. GG&C Guideline

Adults with Incapacity (Scotland) Act 2000. Code of Practice, Scottish Executive. ISBN 0 7557 0396 X

Management of Anaesthesia for Jehovah’s Witnesses – The Association of Anaesthetists of Great Britain and Ireland 2005

Haematological Care of the Jehovah’s Witness Patient, Marsh JCW, Bevan DH – British Journal of Haematology 2002, 119, 25-37

Good Medical Practice (GMC, 2013) 

Caring for patients who refuse blood: A guide to good practice for the surgical practice of Jehovah’s Witnesses and other patients who refuse blood. The Royal College of Surgeons of England 2016